Hyloris Follows On Transaction Scrutiny With Maxigesic IV Updates

The Company’s Partner Secured A Further Deal In Brazil

Following its recently announced leadership changes, Hyloris has made two announcements linked to the marketing of its combined pain therapy Maxigesic IV in Brazil and the US.

Image of Brazilian flag — • Source: Shutterstock

Despite its recently announced leadership changes spurred by continued scrutiny over one of its acquisitions, Hyloris has managed to secure another agreement that will bring its combined pain relief drug Maxigesic IV (paracetamol/ibuprofen) into Brazil.

Established through Hyloris’ partner AFT Pharmaceuticals, the agreement granted exclusive licensing and distribution rights to Brazilian pharma Halex Istar.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

The Generics Bulletin Top 50, Part One: German Giants Rise Up The Ranks

28 Jul 2025

• By Dave Wallace

Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.

Just One Week To Go! Entry Deadline Looms For GGB Awards 2025

25 Jul 2025

• By Dave Wallace

There is now just one week left to submit entries to the Global Generics & Biosimilars Awards 2025, with the entry deadline set for August 1.

‘Europe Has To Make Up Its Mind’ – Medicines For Europe’s Sieger On The Path Ahead

23 Jul 2025

• By Dave Wallace

At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.

European Industry Calls For Support As It Juggles Multiple Challenges

04 Jul 2025

• By Dave Wallace

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.

UK Xtandi Patent Stands Strong As Accord, Sandoz, Teva Lose Appeal

24 Jul 2025

• By Dean Rudge

The Court of Appeal in London has upheld a key UK patent shielding Astellas’ Xtandi, rejecting claims by a trio of generic drugmakers that it was obvious after finding that the generics firms’ expert analysis was tainted by hindsight.